The invention provides a nanoliposomal formulation that targets Integrin Linked Kinase (ILK) with small-interfering RNA (siRNA) in cisplatin-resistant ovarian cancer. A reduction in cell proliferation and invasion was observed upon ILK depletion by siRNA treatment. Furthermore, an ILK-targeted siRNA-liposomal formulation reduced tumor metastasis in an ovarian cancer mouse model. SiRNA-mediated ILK silencing reduced the phosphorylation levels of AKT and GSK3β. The nanoliposomal formulation is formed by lipids and ILK-siRNA according to specific ratios.
